HST Global, Inc. (HSTC)
USD 0.83
(0.0%)
USD 0.83
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -146.21 Thousand USD | -0.78% |
| 2022 | -145.07 Thousand USD | 3.93% |
| 2021 | -151 Thousand USD | 28.1% |
| 2020 | -210 Thousand USD | -149.23% |
| 2019 | 426.57 Thousand USD | 339.2% |
| 2018 | -178.33 Thousand USD | -8.02% |
| 2017 | -165.09 Thousand USD | 4.58% |
| 2016 | -173.02 Thousand USD | 11.63% |
| 2015 | -195.79 Thousand USD | -6.01% |
| 2014 | -184.7 Thousand USD | 4.17% |
| 2013 | -192.73 Thousand USD | 48.73% |
| 2012 | -375.92 Thousand USD | 30.43% |
| 2011 | -540.35 Thousand USD | 36.27% |
| 2010 | -847.85 Thousand USD | 37.78% |
| 2009 | -1.36 Million USD | 9.96% |
| 2008 | -1.51 Million USD | -2057.71% |
| 2007 | 77.3 Thousand USD | 112.04% |
| 2006 | -641.81 Thousand USD | 43.66% |
| 2005 | -1.13 Million USD | -1347.7% |
| 2004 | -78.69 Thousand USD | -115.31% |
| 2003 | 513.84 Thousand USD | 630.8% |
| 2002 | -96.8 Thousand USD | 93.46% |
| 2001 | -1.48 Million USD | -4.97% |
| 2000 | -1.41 Million USD | -571.43% |
| 1999 | -210 Thousand USD | -114.38% |
| 1998 | 1.46 Million USD | 258.7% |
| 1997 | -920 Thousand USD | 72.12% |
| 1996 | -3.3 Million USD | -37.5% |
| 1995 | -2.4 Million USD | -500.0% |
| 1994 | 600 Thousand USD | 220.0% |
| 1993 | -500 Thousand USD | 0.0% |
| 1992 | -500 Thousand USD | -350.0% |
| 1991 | 200 Thousand USD | 300.0% |
| 1990 | -100 Thousand USD | -200.0% |
| 1989 | 100 Thousand USD | 150.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -16.64 Thousand USD | 51.31% |
| 2024 Q1 | -34.17 Thousand USD | 7.38% |
| 2023 FY | -146.21 Thousand USD | -0.78% |
| 2023 Q1 | -41.7 Thousand USD | -16.79% |
| 2023 Q4 | -36.89 Thousand USD | -3.27% |
| 2023 Q3 | -35.73 Thousand USD | -4.18% |
| 2023 Q2 | -34.29 Thousand USD | 17.77% |
| 2022 Q4 | -35.71 Thousand USD | -0.21% |
| 2022 Q2 | -35.51 Thousand USD | 7.07% |
| 2022 Q1 | -38.21 Thousand USD | -7.94% |
| 2022 FY | -145.07 Thousand USD | 3.93% |
| 2022 Q3 | -35.63 Thousand USD | -0.35% |
| 2021 Q3 | -35.34 Thousand USD | 9.1% |
| 2021 Q4 | -35.4 Thousand USD | -0.18% |
| 2021 Q2 | -38.87 Thousand USD | -0.36% |
| 2021 FY | -151 Thousand USD | 28.1% |
| 2021 Q1 | -38.74 Thousand USD | 59.31% |
| 2020 Q3 | -34.93 Thousand USD | 20.66% |
| 2020 Q4 | -95.19 Thousand USD | -172.51% |
| 2020 Q1 | -34.83 Thousand USD | -36.71% |
| 2020 Q2 | -44.02 Thousand USD | -26.4% |
| 2020 FY | -210 Thousand USD | -149.23% |
| 2019 Q4 | -25.48 Thousand USD | -104.71% |
| 2019 Q3 | 540.99 Thousand USD | 1338.11% |
| 2019 Q2 | -43.69 Thousand USD | 3.43% |
| 2019 Q1 | -45.24 Thousand USD | -3.88% |
| 2019 FY | 426.57 Thousand USD | 339.2% |
| 2018 Q4 | -43.55 Thousand USD | 0.05% |
| 2018 Q1 | -46.81 Thousand USD | -8.33% |
| 2018 Q3 | -43.57 Thousand USD | 1.84% |
| 2018 Q2 | -44.39 Thousand USD | 5.17% |
| 2018 FY | -178.33 Thousand USD | -8.02% |
| 2017 Q3 | -16.39 Thousand USD | 62.33% |
| 2017 Q4 | -43.21 Thousand USD | -163.53% |
| 2017 FY | -165.09 Thousand USD | 4.58% |
| 2017 Q1 | -61.94 Thousand USD | -42.42% |
| 2017 Q2 | -43.53 Thousand USD | 29.72% |
| 2016 Q2 | -44.58 Thousand USD | -5.01% |
| 2016 Q1 | -42.45 Thousand USD | 11.28% |
| 2016 Q3 | -42.48 Thousand USD | 4.72% |
| 2016 FY | -173.02 Thousand USD | 11.63% |
| 2016 Q4 | -43.49 Thousand USD | -2.38% |
| 2015 Q3 | -41.42 Thousand USD | 8.32% |
| 2015 FY | -195.79 Thousand USD | -6.01% |
| 2015 Q4 | -47.85 Thousand USD | -15.53% |
| 2015 Q1 | -61.33 Thousand USD | -38.58% |
| 2015 Q2 | -45.18 Thousand USD | 26.34% |
| 2014 FY | -184.7 Thousand USD | 4.17% |
| 2014 Q3 | -46.77 Thousand USD | 1.27% |
| 2014 Q2 | -47.37 Thousand USD | -2.33% |
| 2014 Q1 | -46.29 Thousand USD | -9.29% |
| 2014 Q4 | -44.25 Thousand USD | 5.37% |
| 2013 Q3 | -46.07 Thousand USD | 28.66% |
| 2013 FY | -192.73 Thousand USD | 48.73% |
| 2013 Q4 | -42.36 Thousand USD | 8.06% |
| 2013 Q2 | -64.59 Thousand USD | -62.67% |
| 2013 Q1 | -39.7 Thousand USD | 55.68% |
| 2012 Q3 | -91.47 Thousand USD | 16.25% |
| 2012 Q4 | -89.59 Thousand USD | 2.06% |
| 2012 Q2 | -109.22 Thousand USD | -27.54% |
| 2012 Q1 | -85.63 Thousand USD | 68.72% |
| 2012 FY | -375.92 Thousand USD | 30.43% |
| 2011 Q1 | -85.63 Thousand USD | 45.5% |
| 2011 Q2 | -98.96 Thousand USD | -15.57% |
| 2011 Q3 | -81.97 Thousand USD | 17.16% |
| 2011 Q4 | -273.77 Thousand USD | -233.96% |
| 2011 FY | -540.35 Thousand USD | 36.27% |
| 2010 Q4 | -157.11 Thousand USD | -0.99% |
| 2010 Q3 | -155.58 Thousand USD | 49.96% |
| 2010 Q2 | -310.9 Thousand USD | -38.64% |
| 2010 FY | -847.85 Thousand USD | 37.78% |
| 2010 Q1 | -224.24 Thousand USD | 38.52% |
| 2009 Q1 | -324.11 Thousand USD | -35.46% |
| 2009 FY | -1.36 Million USD | 9.96% |
| 2009 Q4 | -364.74 Thousand USD | -15.06% |
| 2009 Q3 | -317.01 Thousand USD | 11.14% |
| 2009 Q2 | -356.74 Thousand USD | -10.07% |
| 2008 Q3 | -434.49 Thousand USD | 39.66% |
| 2008 FY | -1.51 Million USD | -2057.71% |
| 2008 Q2 | -720.08 Thousand USD | -881.8% |
| 2008 Q1 | -73.34 Thousand USD | -141.54% |
| 2008 Q4 | -239.26 Thousand USD | 44.93% |
| 2007 Q3 | 121.54 Thousand USD | -44.95% |
| 2007 Q1 | -204.81 Thousand USD | 88.71% |
| 2007 Q4 | 176.54 Thousand USD | 45.25% |
| 2007 Q2 | 220.78 Thousand USD | 207.8% |
| 2007 FY | 77.3 Thousand USD | 112.04% |
| 2006 Q1 | -88.94 Thousand USD | 92.95% |
| 2006 Q2 | 998.73 Thousand USD | 1222.84% |
| 2006 Q4 | -1.81 Million USD | -792.78% |
| 2006 Q3 | 261.74 Thousand USD | -73.79% |
| 2006 FY | -641.81 Thousand USD | 43.66% |
| 2005 Q4 | -1.26 Million USD | -873.53% |
| 2005 FY | -1.13 Million USD | -1347.7% |
| 2005 Q2 | -16.27 Thousand USD | 31.63% |
| 2005 Q3 | 163.19 Thousand USD | 1102.52% |
| 2005 Q1 | -23.8 Thousand USD | 29.48% |
| 2004 FY | -78.69 Thousand USD | -115.31% |
| 2004 Q4 | -33.76 Thousand USD | -49.46% |
| 2004 Q3 | -22.58 Thousand USD | -84.11% |
| 2004 Q2 | -12.26 Thousand USD | -21.79% |
| 2004 Q1 | -10.07 Thousand USD | 80.04% |
| 2003 Q1 | 133.23 Thousand USD | -68.21% |
| 2003 Q2 | -15 Thousand USD | -111.26% |
| 2003 Q3 | 446.07 Thousand USD | 3073.85% |
| 2003 Q4 | -50.46 Thousand USD | -111.31% |
| 2003 FY | 513.84 Thousand USD | 630.8% |
| 2002 Q4 | 419.04 Thousand USD | 215.87% |
| 2002 Q2 | -136.26 Thousand USD | -668.4% |
| 2002 Q1 | -17.73 Thousand USD | -125.33% |
| 2002 Q3 | -361.65 Thousand USD | -165.41% |
| 2002 FY | -96.8 Thousand USD | 93.46% |
| 2001 FY | -1.48 Million USD | -4.97% |
| 2001 Q4 | 70 Thousand USD | 107.29% |
| 2001 Q3 | -960 Thousand USD | -405.26% |
| 2001 Q2 | -190 Thousand USD | -171.43% |
| 2001 Q1 | -70 Thousand USD | 93.91% |
| 2000 Q4 | -1.15 Million USD | -483.33% |
| 2000 Q3 | 300 Thousand USD | 156.6% |
| 2000 Q2 | -530 Thousand USD | -1666.67% |
| 2000 Q1 | -30 Thousand USD | 57.14% |
| 2000 FY | -1.41 Million USD | -571.43% |
| 1999 Q3 | - USD | 100.0% |
| 1999 Q2 | -90 Thousand USD | -50.0% |
| 1999 Q4 | -70 Thousand USD | 0.0% |
| 1999 FY | -210 Thousand USD | -114.38% |
| 1999 Q1 | -60 Thousand USD | 76.0% |
| 1998 FY | 1.46 Million USD | 258.7% |
| 1998 Q4 | -250 Thousand USD | -219.05% |
| 1998 Q3 | 210 Thousand USD | -86.45% |
| 1998 Q2 | 1.55 Million USD | 2683.33% |
| 1998 Q1 | -60 Thousand USD | 93.26% |
| 1997 Q1 | - USD | 100.0% |
| 1997 Q4 | -890 Thousand USD | -169.7% |
| 1997 Q3 | -330 Thousand USD | -213.79% |
| 1997 FY | -920 Thousand USD | 72.12% |
| 1997 Q2 | 290 Thousand USD | 0.0% |
| 1996 Q3 | - USD | 100.0% |
| 1996 FY | -3.3 Million USD | -37.5% |
| 1996 Q1 | -300 Thousand USD | 80.0% |
| 1996 Q2 | -100 Thousand USD | 66.67% |
| 1996 Q4 | -2.9 Million USD | 0.0% |
| 1995 Q1 | - USD | -100.0% |
| 1995 Q4 | -1.5 Million USD | -36.36% |
| 1995 Q3 | -1.1 Million USD | -1200.0% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1995 FY | -2.4 Million USD | -500.0% |
| 1994 Q4 | 100 Thousand USD | 0.0% |
| 1994 Q1 | 200 Thousand USD | 300.0% |
| 1994 FY | 600 Thousand USD | 220.0% |
| 1994 Q2 | 200 Thousand USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | -50.0% |
| 1993 Q2 | -200 Thousand USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 FY | -500 Thousand USD | 0.0% |
| 1993 Q3 | -200 Thousand USD | 0.0% |
| 1993 Q4 | -100 Thousand USD | 50.0% |
| 1992 FY | -500 Thousand USD | -350.0% |
| 1992 Q1 | 100 Thousand USD | 150.0% |
| 1992 Q2 | 100 Thousand USD | 0.0% |
| 1992 Q3 | -100 Thousand USD | -200.0% |
| 1992 Q4 | - USD | 100.0% |
| 1991 Q4 | -200 Thousand USD | -300.0% |
| 1991 Q1 | 100 Thousand USD | 0.0% |
| 1991 FY | 200 Thousand USD | 300.0% |
| 1991 Q3 | 100 Thousand USD | -50.0% |
| 1991 Q2 | 200 Thousand USD | 100.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1990 Q2 | - USD | -100.0% |
| 1990 Q3 | -100 Thousand USD | 0.0% |
| 1990 Q4 | - USD | 100.0% |
| 1990 FY | -100 Thousand USD | -200.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 FY | 100 Thousand USD | 150.0% |
| 1989 Q1 | 100 Thousand USD | 133.33% |
| 1989 Q2 | 100 Thousand USD | 0.0% |
| 1989 Q3 | - USD | -100.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 89.051% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 97.906% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.276% |
| Nascent Biotech, Inc. | -2.08 Million USD | 92.997% |
| Rebus Holdings, Inc. | -1.02 Million USD | 85.666% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.224% |
| Qrons Inc. | -789.34 Thousand USD | 81.477% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 76.88% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.766% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 64.809% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.612% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.805% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 97.777% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 46.522% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.816% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 94.945% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 91.969% |
| Mesoblast Limited | -87.95 Million USD | 99.834% |
| Marizyme, Inc. | -65.34 Million USD | 99.776% |
| Genus plc | 7.9 Million USD | 101.851% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 98.658% |
| Pharming Group N.V. | -10.54 Million USD | 98.614% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 93.262% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 96.059% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 98.347% |
| ContraFect Corporation | -65.15 Million USD | 99.776% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 97.008% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 91.536% |
| IMV Inc. | -36.48 Million USD | 99.599% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 98.186% |
| MultiCell Technologies, Inc. | -380.07 USD | -38369.229% |
| ONE Bio Corp. | 8.67 Million USD | 101.685% |
| Accustem Sciences Inc. | -3.74 Million USD | 96.097% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.717% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 88.461% |
| Q BioMed Inc. | -2.05 Million USD | 92.875% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 96.083% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 93.859% |
| Biomind Labs Inc. | -1.21 Million USD | 87.96% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.755% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 95.286% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 98.15% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 92.499% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -876.295% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 99.079% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 97.487% |
| GB Sciences, Inc. | -1.36 Million USD | 89.263% |
| Alpha Cognition Inc. | -13.77 Million USD | 98.938% |
| CSL Limited | 2.64 Billion USD | 100.006% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 91.668% |
| Halberd Corporation | -79.67 Thousand USD | -83.506% |
| Enzolytics Inc. | -2.17 Million USD | 93.283% |
| Agentix Corp. | -1.37 Million USD | 89.36% |
| Resverlogix Corp. | -3.61 Million USD | 95.95% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 95.39% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.95% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 249.194% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 102.111% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 96.32% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 95.168% |
| AVAX Technologies, Inc. | -6.41 Million USD | 97.72% |
| Zenith Capital Corp. | -10.59 Million USD | 98.62% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.847% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -529.077% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 96.473% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -141.907% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 92.708% |
| Kadimastem Ltd | -3.3 Million USD | 95.579% |
| Helix BioMedix, Inc. | -1.05 Million USD | 86.155% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 96.172% |
| BioStem Technologies, Inc. | -8.48 Million USD | 98.276% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 66.874% |
| LadRx Corporation | 400.44 Thousand USD | 136.512% |
| Cell Source, Inc. | -5.32 Million USD | 97.252% |
| Regen BioPharma, Inc. | 1.02 Million USD | 114.285% |
| Regen BioPharma, Inc. | 1.02 Million USD | 114.285% |
| NovAccess Global Inc. | -4.76 Million USD | 96.934% |
| Affymax, Inc. | -14.42 Million USD | 98.986% |
| Itoco Inc. | -1.86 Million USD | 92.177% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 96.709% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 91.24% |
| Mobile Lads Corp. | -2.26 Million USD | 93.54% |
| CytoDyn Inc. | -49.84 Million USD | 99.707% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -84.999% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 35.909% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 84.471% |
| SYBLEU INC | -180.3 Thousand USD | 18.909% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 90.934% |
| International Stem Cell Corporation | -131 Thousand USD | -11.611% |
| Bioxytran, Inc. | -4.28 Million USD | 96.584% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -169.402% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 94.222% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.696% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 93.084% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 81.276% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 95.385% |
| Neutra Corp. | -233.46 Thousand USD | 37.374% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 99.279% |
| PureTech Health plc | -65.69 Million USD | 99.777% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 99.312% |
| IXICO plc | -1.17 Million USD | 87.588% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 98.527% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.744% |
| CSL Limited | 2.64 Billion USD | 100.006% |
| Cellectis S.A. | -103.17 Million USD | 99.858% |